Literature DB >> 19667978

Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders.

Sultan Tarlaci1.   

Abstract

There is evidence that some antidepressant drugs are beneficial in the prophylaxis of migraine. Previous reports have shown that migraine patients may respond to various antidepressant agents used for prophylactic therapy. The main purpose of this study was to compare the efficacy of antidepressants from 2 different groups (venlafaxine vs escitalopram) on people who had migraine headache without depression or anxiety. In this prospective study, we evaluated the headache diaries of 93 patients who were being treated with venlafaxine (n = 35) and escitalopram (n = 58). At the end of the 3-month period, patients were reassessed, and those with marked differences in attack frequency, duration, intensity (with visual analog scales), lost work-day equivalent index, and migraine disability assessment questionnaire were compared. There was a clear reduction in headache frequency (P < 0.0001), duration (P < 0.0001), and severity (P < 0.0001) in the venlafaxine group. In addition, there was a significant improvement in daily work performance during headaches (P < 0.0001). In the escitalopram group, monthly headache frequency (P < 0.026), duration (P < 0.002), and intensity (P < 0.027) all decreased significantly, although not to the same extent as with venlafaxine. After the third month of venlafaxine and escitalopram treatment, most of the patients (82.8% vs 96.5%) were seen to have moved to the minimal or infrequent migraine disability assessment group. According to our findings, venlafaxine and escitalopram are both effective in the prophylaxis of migraine headache without depression and anxiety. This effect was independent of mood disorder. Escitalopram should be the first choice because of its fewer side effects, but venlafaxine may be used if escitalopram is found to be insufficient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667978     DOI: 10.1097/WNF.0b013e3181a8c84f

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  7 in total

Review 1.  Chronic Daily Headache: Mechanisms and Principles of Management.

Authors:  Amy W Voigt; Harry J Gould
Journal:  Curr Pain Headache Rep       Date:  2016-02

Review 2.  Current Treatment Options: Headache Related to Menopause-Diagnosis and Management.

Authors:  Clinton G Lauritsen; Abigail L Chua; Stephanie J Nahas
Journal:  Curr Treat Options Neurol       Date:  2018-03-06       Impact factor: 3.598

Review 3.  Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.

Authors:  Rita Banzi; Cristina Cusi; Concetta Randazzo; Roberto Sterzi; Dario Tedesco; Lorenzo Moja
Journal:  Cochrane Database Syst Rev       Date:  2015-04-01

4.  Commentary: Distribution of 5-HT1F Receptors in Monkey Vestibular and Trigeminal Ganglion Cells.

Authors:  Marcelo M Valença
Journal:  Front Neurol       Date:  2016-12-20       Impact factor: 4.003

Review 5.  Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines.

Authors:  Lorena Dima; Andreea Bălan; Marius Alexandru Moga; Cătălina Georgeta Dinu; Oana Gabriela Dimienescu; Ioana Varga; Andrea Elena Neculau
Journal:  Toxins (Basel)       Date:  2019-08-08       Impact factor: 4.546

Review 6.  Acute and Preventive Management of Migraine during Menstruation and Menopause.

Authors:  Raffaele Ornello; Eleonora De Matteis; Chiara Di Felice; Valeria Caponnetto; Francesca Pistoia; Simona Sacco
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

7.  Italian guidelines for primary headaches: 2012 revised version.

Authors:  Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin
Journal:  J Headache Pain       Date:  2012-05       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.